@PROMISE_Trial @vtkronsten

To trainees attending the upcoming #BASL2025 meeting, trainees’ committee has organised a meet & greet session! Great opportunity to network, foster new collaborations & speak with regional trainee reps! Meeting room 3, Friday, 10:45am! baslannualmeeting.org.uk/wp-… @BASLedu

Cirrhosis can be depressing: a nationwide cohort study

🔥 New insights on Autoimmune Hepatitis (AIH) treatment! 🔬 From personalized thiopurine therapy 💊 to mycophenolate mofetil (MMF) as a 1st-line option, and advanced biologics like infliximab & rituximab 🌟—discover strategies to tackle difficult-to-treat AIH and improve patient outcomes. 🩺💡 Read the full paper by @MichaelHenegha in @FrontGastro_BMJ 📚 here -> fg.bmj.com/content/early/202… #Livertwitter #AutoimmuneHepatitis #AIH #LiverHealth #PersonalizedMedicine #Biologics #Gastroenterology #MedicalResearch @BASLedu @BritSocGastro @EASLnews @EASLedu @AASLDtweets @PhilSmithIsBack @dr_aditi_kumar @OTavabie @DrJMKennedy @DunnePdj @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman

Last week, clinical teams from across the UK recruiting to the PROMISE trial came together at King's to share insights and learnings. They were joined by patient representatives who shared their stories and experiences of being part of the trial. Speaking of the day, Chief Investigator of the trial @DebbieShawcros1 said: "It was an absolute privilege to bring together colleagues and patients from our 20 clinical sites across the UK to share our experiences and knowledge of being part of the PROMISE Trial. It was particularly humbling to hear the personal experiences of our patients enrolled on the trial and to hear the benefits of participating in clinical research tackling the complications of liver disease." bit.ly/4mbb7Dx

Nice profile of our work just out in Nature nature.com/articles/d41586-0…

Following the @EASLnews annual congress earlier this month in Amsterdam, we’re celebrating our very own Prof. @DebbieShawcros1 and her new role as Secretary General of EASL, a key post within the international landscape of liver research 👏👏 Full article: liver-research.org.uk/news/9…

Today is World Clinical Trials Day! Thank you everyone for your ongoing support on PROMISE🥳👏 - see our new blog on the @LiverTrust website: The PROMISE trial – get involved in research looking at a very different type of medicine. #ClinicalTrial #NIHRresearch @DebbieShawcros1

Don’t miss the Rare Liver Disease Masterclass! 15–16 June 2025 | London Hear from international experts on Wilson’s Disease, cholestatic liver disorders, alpha-1 antitrypsin deficiency, clinical trials & more. 🔗 Full programme : bit.ly/MasterclassProgramme2… – register now!

Great to see #JadeKing any my editorial in @LTxJournal journals.lww.com/lt/citation… discussing the psychological and cognitive impact of liver disease and transplantation on patients as well as the potential role of prehabilitation in addressing this @liverphysio

This was my absolute highlight of #ECCO2025 So glad I stayed late to hear the big reveal. Low emulsifier diets will change clinical and patient’s lives. Massive congratulations @ProfWhelan & @AaronBancil

📢Adolescent sobriety under siege ➡️An urgent call to protect children from alcohol harms ➡️EASL calls on all countries to establish and enact comprehensive strategies to mitigate alcohol-related harms 🔗journal-of-hepatology.eu/art… #LiverTwitter @EASLnews @EASLedu @EASLEUAffairs

Very proud to have this published! Thank you to the Lancet and it’s incredible editorial team for your collaboration on this project. Some important updates, hope you find it useful! Appendix has lots of information about pregnancy in AIH, PBC, PSC and Wilson’s too. @MichaelHenegha8 @cathwilliamson5 @TheBileDoc @joostphdrenth @STGHepatology @arjybargy

❌💊 Simvastatin rifaximin does not prevent ACLF development in decompensated cirrhosis ⏳10 years of work in the books 💪🏼 @salvatore_piano @Zac_MD @KGananandan @UschnerFrank @JonelTrebicka @ruben_hernaez @JuanAbraldes @JordiGratacos8 @dewitkoos @EASLnews @AASLDtweets

PhD/MD opportunity, clinical research fellow post (ST4 ) to start in September 2025. Post-CCT individuals welcome. Come and join our wonderful, friendly, diverse and fun (!) team. Link below, please share with anyone who might be interested. Don’t be shy, come have a chat! @BSGTrainees @arjybargy @DebbieShawcros1 @vtkronsten @OTavabie @Drwenhaoli

Happy to announce that we have achieved 💯out of 300 randomisations in the PROMISE trial. Thank you everyone for your amazing work, let's keep going in 2025! #FMT #clinicaltrials #livercirrhosis @DebbieShawcros1 @vtkronsten

A great start to 2025! 1st participant randomised by the Nottingham team! @NHSNotts 9⃣9⃣ recruited, 1 more to 💯! Happy New Year everyone! #fmt #clinicaltrials #liver #cirrhosis @DebbieShawcros1 @vtkronsten

Delighted to share @vtkronsten recent review in @AmJGastro Clinical Implications of Inflammation in Patients With Cirrhosis journals.lww.com/ajg/fulltex… @JasmohanBajaj @kingsmedicine @KingsCollegeNHS @Inst_of_Liver

How to differentiate depression & anxiety from encephalopathy? How can we safely treat them when the patient doesn't want to go to a mental health specialist? This review on depression & anxiety in cirrhosis is very useful. t.ly/F49bD

After highlighting the steep rise in alcohol-related liver disease in young women, we now highlight an even bigger problem in our children. The highest prevalence of lifetime alcohol use for 11-year-olds (34% girls) was observed in the UK. @Inst_of_Liver doi.org/10.1016/j.jhep.2024.…